ypertrophic cardiomyopathy (HCM) is functionally characterized by normal or supernormal left ventricular systolic function and impaired left ventricular diastolic function, and the severity of left ventricular diastolic dysfunction is related to exercise capacity, clinical symptoms and even prognosis. [1] [2] [3] The impairment of left ventricular diastolic function in patients with HCM is closely related to intracellular Ca 2+ overload and is also known to be frequency dependent. 4 Therefore, calcium antagonists are a rational choice for the treatment of HCM and many studies have reported improvement of diastolic function with these agents. However, the effect of calcium antagonists is often insufficient in many patients with HCM.
the left ventricular diastolic function in patients with HCM by evaluating the changes of left ventricular function associated with cibenzoline treatment in patients with both HOCM and hypertrophic nonobstructive cardiomyopathy (HNCM).
Methods

Study Patients
Nineteen patients with HCM were enrolled after giving informed consent, and were divided into 12 cases of HOCM and 7 of HNCM ( Table 1 ). The diagnosis of HCM was made by echocardiography based on the World Health Organization/International Society and Federation of Cardiology definition of cardiomyopathies. 10 HOCM was diagnosed when the HCM patient had a LVPG more than 30 mmHg without provocation. The LVPG, which was determined by the Doppler approach with the Bernoulli equation, 11 ranged between 41 and 154 mmHg. The level of obstruction was in the subaortic region in 9 patients and in the mid-left ventricular cavity in 3. One patient with a midventricular obstruction participated in this study after giving informed consent. Patients who had systemic hypertension, significant valvular heart disease, or any other systemic conditions that might cause cardiac hypertrophy were excluded.
H Japanese Circulation Journal Vol.65, June 2001
min before and 2 h after administration of an oral dose of 200 mg of cibenzoline (2 h after administration is the expected time of maximal plasma concentration, 12 which we had previously measured and confirmed 7 ).
M-Mode and Doppler Echocardiography
Echocardiographic studies were carried out with an SSD-9000 echocardiograph with a 3.5-MHz transducer (ALOKA Inc, Tokyo, Japan). The following parameters were measured from M-mode echocardiographic recordings according to the criteria of the American Society of Echocardiography 13 : interventricular septal thickness, left ventricular posterior wall thickness, left ventricular internal dimensions at enddiastole and end-systole and fractional shortening. LVPG, peak A-wave and peak E-wave velocities and the ratio of E-wave velocity to A-wave velocity (E/A ratio) were measured from continuous-wave Doppler recordings. The peak shortening speed and peak lengthening speed of the left ventricular posterior wall were calculated with the aid of a computer interfaced with a graphic analyzer (model Cardio 500, Kontron Electronik, Eching, Germany). All measurements were carried out over 3 cardiac cycles. Continuouswave Doppler and M-mode echocardiograms were recorded at a paper speed of 100 mm/s. Normal values in our laboratory are 47.2±3.8 mm in left ventricular internal dimensions at end-diastole, 28.3±3.9 mm in left ventricular internal dimensions at end-systole and 40.1±6.0% in fractional shortening. 14 Mechanocardiography Systolic time intervals were determined as reported previously. 15, 16 To measure total mechanical systole (Q-II interval), left ventricular ejection time and pre-ejection period, simultaneous recordings of the ECG, phonocardiogram and carotid pulse tracing at a paper speed of 100 mm/s were performed with an MIC-8800 polygraph (Fukuda Denshi Co Ltd). These measurements were also done by heart rate-corrected values with the regression equations of Weissler et al. 17 In addition, the time between the aortic component of the second heart sound and the O point of the apexcardiogram (IIa-O time) was also measured to confirm the change in left ventricular diastolic function. Normal ranges in our laboratory are 279±15 ms in left ventricular ejection time, 115±10 ms in pre-ejection period 15 and 119±9 ms in IIa-O time. 18 Gated Radionuclide Angiography Gated radionuclide were corrected by body surface area.
Statistical Analysis
All values are expressed as mean ± SD. Data obtained before and after administration of cibenzoline were compared by Student's t test for paired samples. A value of p<0.05 was considered significant. (Table 1) Heart rate remained unchanged before and after administration of cibenzoline. Blood pressures remained unchanged from 130±14/81±7 to 129±13/81±5 mmHg in patients with HOCM, and from 128±12/81±7 to 128±11/80±5 mmHg in patients with HNCM.
Results
Changes in the Echocardiographically Determined Parameters
Left ventricular end-diastolic dimension remained unchanged and left ventricular end-systolic dimension increased and thus, fractional shortening decreased after cibenzoline. E-wave velocity increased, A-wave velocity decreased and E/A ratio increased in both HOCM and HNCM. LVPG decreased in all patients with HOCM (Fig 1) . Fig 2 shows the changes in the continuous wave Doppler flow pattern in the left ventricular outflow tract and the transmitral Doppler flow pattern before and after administration of cibenzoline in a patient with HOCM (patient 1). A marked attenuation of LVPG and an increase of the E/A ratio were observed. The peak shortening speed of the left ventricular posterior wall remained unchanged, but peak lengthening speed increased in patients with both HOCM and HNCM after cibenzoline (Fig 3) . After cibenzoline, despite the increase of left ventricular end-systolic dimension, peak lengthening speed increased, but, peak lengthening speed after the ectopic beat decreased despite the decrease of left ventricu- 418  428  532  548  325  294  416  390  93  134  116  158  272  174  368  375  500  520  265  250  372  367  103  125  128  153  224  170  476  458  574  552  342  320  420  395  134  138  154  157  298  182  409  444  510  539  253  261  335  338  156  183  175  201  286  176  428  436  536  546  297  282  383  370  131  154  153  176  238  166  428  388  546  527  304  254  399  366  124  134  146  160  285  187  430  458  534  554  296  302  379  379  134  156  155  175  232  198  379  381  524  541  296  276  413  405  83  105  111  135  290  196  386  410  489  523  270  284  353  376  116  126  136  148  310  212  437  440  582  558  292  242  409  337  145  198  173  220  290 lar end-systolic dimension.
Changes in the Mechanocardiographic Patterns (Table 2)
The left ventricular ejection time and left ventricular ejection time index were shortened, and the pre-ejection period and pre-ejection period index were prolonged in patients with both HOCM and HNCM after administration of cibenzoline. On the other hand, IIa-O time was markedly shortened in both HOCM and HNCM. Fig 4 shows the representative change of apexcardiogram before and after cibenzoline in a patient with mid-ventricular obstruction (patient 2). In addition to a marked shortening of IIa-O time, the patterns of carotid pulse tracing and rapid filling phase reverted to nearly normal after administration of cibenzoline.
Changes in the Parameters Estimated by Gated
Radionuclide Angiography (Table 3) Both ejection fraction and peak ejection rate decreased in HOCM and HNCM patients after administration of cibenzoline. Of the left ventricular diastolic functions, peak filling rate remained unchanged, but time to peak filling rate was markedly shortened in both HOCM and HNCM patients. Fig 5 and 6 show the representative changes of the time-activity curve and its first derivative curve in a patient with HOCM (patient 1) and a patient with HNCM (patient 6), respectively. Ejection fraction decreased in both patients, but time to peak filling rate was markedly shortened after administration of cibenzoline. End-diastolic volume index remained unchanged in patients with HOCM, but increased in patients with HNCM after administration of cibenzoline. End-systolic volume index increased in both HOCM and HNCM patients. Stroke index and cardiac index decreased in both HOCM and HNCM. Fig 7 shows the changes of aortic and left ventricular pressures associated with the intravenous administration of cibenzoline of 1.4 mg/kg for 5 min in a 61-year-old man with mid-ventricular obstruction. The LVPG disappeared 120 s after administration, and the left ventricular pressure and heart rate remained unchanged. Left ventricular enddiastolic pressure and left ventricular minimal pressure markedly decreased from 32 mmHg to 16 mmHg, and 4 mmHg to -6 mmHg, respectively. In addition, an increase in the LVPG after a short run was not observed.
Effect of Intravenous Administration of Cibenzoline
Discussion
Left ventricular systolic functions were suppressed, but diastolic functions were dramatically improved by cibenzoline in HCM patients, whether they had HOCM or HNCM. Thus, the beneficial effect of cibenzoline in patients with HCM is due mainly to its direct effect, not an indirect effect associated with the reduction of LVPG.
Effect of Cibenzoline on LVPG
The LVPG disturbs the ejection dynamics in patients with HOCM and may be related to the clinical symptoms. Both -blockers and calcium antagonists have been widely used for the treatment of HCM, but are often insufficient to relieve the obstruction associated with the LVPG. In addition to useful methods such as myotomy or myectomy, 19 DDD pacing therapy 20, 21 and transcoronary ablation of septal hypertrophy [22] [23] [24] have resulted in significant attenuation of the LVPG. In 1997, we reported that cibenzoline could dramatically attenuate LVPG 7 and we have confirmed the strong effect of cibenzoline on LVPG attenuation in the present HOCM patients with both subaortic region and mid-left ventricular cavity obstruction. The negative inotropic action of cibenzoline 25 may be closely related to this effect, which was recently reconfirmed by Sherrid et al. 26 
Effect of Cibenzoline on Left Ventricular Systolic Function
Most parameters of systolic function were significantly suppressed after cibenzoline in patients with HOCM or HNCM. However, fractional shortening values showed, after cibenzoline FS remained normal in patients with HNCM and even supernormal in patients with HOCM. In addition, the peak shortening speed of the left ventricular posterior wall remained unchanged after cibenzoline. These findings indicate that the suppressive effect of cibenzoline on systolic function may be not so severe in patients with HCM.
Ejection performances reflected by stroke volume index and cardiac index were also suppressed by cibenzoline. Normal ranges in our laboratory of these parameters estimated by dye-dilution method using a cuvette densitometer are 64±9 ml·beat -1 ·m -2 and 3.81±0.37 L·min -1 ·m -2 , respectively, and that for left ventricular end-diastolic volume index is 76±13 ml/m 2 . 15 Compared with these values, the stroke volume index and cardiac index in HCM were markedly low even before cibenzoline and may be due to the markedly low end-diastolic volume index. Shortening of the left ventricular ejection time after cibenzoline may be closely related to the decrease in stroke volume. Increasing the end-diastolic volume index after cibenzoline may be the correction of cardiac performance in the near future.
Some class Ia antiarrhythmic drugs have a negative inotropic action, 27 although the exact mechanism of the negative inotropic action of cibenzoline is unknown. However, it is highly conceivable that the decrease in intracellular Ca 2+ concentration according to the inhibition of Na + influx by administration of cibenzoline and its Ca 2+ -channelblocking property is closely related to this mechanism.
Effect of Cibenzoline on Left Ventricular Diastolic Function
Analysis of the transmitral Doppler flow pattern is useful in estimating left ventricular filling pressure in patients with left ventricular dysfunction, 28 but cannot be done in patients with HCM, so we used 3 other methods to evaluate the effect of cibenzoline on left ventricular diastolic function. The first was direct estimation of filling velocity of left ventricular posterior wall by M-mode echocardiography, and then the IIa-O time on the apexcardiogram, which is markedly prolonged in patients with HCM. 18 Calcium antagonists markedly shorten this interval, but -blockers do not. 29 The O-point corresponds approximately to the nadir of left ventricular pressure and thus, this marker is a good indicator of the impairment of left ventricular relaxation and filling. 30 The third method is volumetric analysis by gated radionuclide angiography.
In the present study, most left ventricular diastolic functions were markedly improved in both HOCM and HNCM patients, which was not due to the reduction of LVPG, but to the direct action of cibenzoline. In an experimental study using ventricular muscle from patients with HCM, Gwathmey et al clearly indicated that intracellular Ca 2+ overload was closely related to diastolic dysfunction in HCM. 4 Cibenzoline has a strong myocardial Na + -channel blocking action, which results in a decrease in intracellular Ca 2+ concentration. 6 In addition, cibenzoline has a Ca 2+ -channel-blocking property. Thus, the beneficial effect of cibenzoline on left ventricular diastolic function in HCM seems to be due mainly to the marked attenuation of intracellular Ca 2+ overload produced by both Ca 2+ -and Na + -channel blocking actions. Patients with HCM respond in a paradoxical manner to stimuli 31 and in the present study, the left ventricular systolic and diastolic functions responded in this way to cibenzoline. However, all the hemodynamic data associated with cibenzoline administration may be the result of the decrease in intracellular Ca 2+ concentration, causing systolic functions to change from supernormal to normal, and diastolic function to improve.
Comparison Between Cibenzoline and Calcium Antagonists or Other Drugs
We have demonstrated that that cibenzoline can directly improve left ventricular diastolic function in patients with HCM and that the mechanism must be a decrease in intracellular Ca 2+ concentration. The myocardial Ca 2+ -channel blocking effect of cibenzoline is about one-fiftieth compared with verapamil, 6 but its clinical efficacy is better. Bonow et al investigated the acute and chronic effects of verapamil on left ventricular functions in patients with HCM and found that in their acute study, ejection fraction decreased, the peak filling rate remained unchanged and the time to peak filling rate was shortened by 8.7%, 32, 33 results that are identical to those of the present study. In their chronic study, the time to peak filling rate was shortened by 18% and in the present study, it was shortened by 23% in HOCM and by 25% in HNCM. This strong effect of cibenzoline may be due to its myocardial Na + -channel blocking action and so because of its blocking effect of both the Ca 2+ and Na + channels, the intracellular Ca 2+ concentration may be lower in patients given cibenzoline than in those taking verapamil.
In our study, both the systolic and diastolic pressures and the heart rate remained unchanged after oral and intravenous administration of cibenzoline indicating that its effect on vasodilatation and its negative chronotropic action may be weak. In addition, intravenous administration of cibenzoline to a patient with HOCM elucidated that cibenzoline could attenuate both left ventricular end-diastolic and left ventricular minimal pressures, which had been hypothesized by us. 7, 34 Disopyramide is known to be effective in attenuating left ventricular diastolic dysfunctions such as early diastolic time intervals and transmitral Doppler flow patterns in patients with HCM, 35, 36 an effect that is identical to diltiazem. 36 We also elucidated here that cibenzoline can attenuate the impairment of early diastolic time intervals and transmitral Doppler flow patterns in both HOCM and HNCM patients and so we believe that the effect of cibenzoline on HOCM is basically identical to that of disopyramide.
On the other hand, -blockers can do little to improve left ventricular diastolic function in patients with HCM because they decrease intracellular Ca 2+ through decreasing the cyclic AMP concentration, which attenuates the ability of the sarcoplasmic reticulum to sequester calcium and the lower intracellular Ca 2+ concentration. Therefore, -blockers suppress myocardial contractility, but cannot improve left ventricular diastolic function in HCM. 29, 31 Clinical Implications
The present study provides the first direct evidence that cibenzoline can potently improve left ventricular diastolic dysfunction in both HOCM and HNCM patients. A very mild anticholinergic action 37 and a stimulation-frequency dependent enhancement of the intracellular Ca 2+ current blocking action of cibenzoline 5 would be very desirable for clinical use. However, the beneficial effect of cibenzoline is based on the decrease in intracellular Ca 2+ which results in a decrease in myocardial contractility. In fact, in the present study, left ventricular systolic function was suppressed by cibenzoline. The intracellular Ca 2+ concentration in patients with HCM, even in patients with end-stage heart failure, is very high, 4 so the depression of left ventricular systolic function is mild or ngligible. Nevertheless, cibenzoline should be used with care in patients with HCM, especially if there are dilated cardiomyopathy-like features. Cibenzoline belongs to the class Ia antiarrhythmic drugs, which normally prolong the QT interval through prolongation of the action potential duration at the cellular level. Long QT is a condition characterized by abnormal cardiac repolarization and can lead to the development of polymorphic ventricular tachycardia and, in some cases, syncope or sudden cardiac death. Thus, any change of the QT interval when cibenzoline is used must be taken seriously.
